A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Clinical Operations
- Email: env-294.clinicaltrials@enveda.com
Study Locations
-
-
California
-
Encinitas, California, United States, 92024
- Recruiting
- Enveda Investigative Site
-
Los Angeles, California, United States, 90045
- Recruiting
- Enveda Investigative Site
-
Northridge, California, United States, 91325
- Recruiting
- Enveda Investigative Site
-
-
Florida
-
Boca Raton, Florida, United States, 33486
- Recruiting
- Enveda Investigative Site
-
-
Indiana
-
Indianapolis, Indiana, United States, 46250
- Recruiting
- Enveda Investigative Site
-
Plainfield, Indiana, United States, 46168
- Recruiting
- Enveda Investigative Site
-
-
Texas
-
Dallas, Texas, United States, 75230
- Recruiting
- Enveda Investigative Site
-
San Antonio, Texas, United States, 78213
- Recruiting
- Enveda Investigative Site
-
Sugar Land, Texas, United States, 77479
- Recruiting
- Enveda Investigative Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
In order to participate in this study all participants must:
- Be at least 18 years of age at the time of signing the ICF.
- Have chronic AD (also known as atopic eczema) that was diagnosed at least 12 months prior to Screening.
- Have a history of inadequate response or intolerance to topical corticosteroids or other topical treatments for AD within 6 months before Screening and/or inadequate response to a systemic therapy within 12 months before Screening.
Have moderate-to-severe AD, at Screening and Baseline, as defined by the following criteria:
- A vIGA score of 3 (moderate) or 4 (severe)
- EASI score of ≥16
- Body surface area involvement of ≥10%
- Have PP-NRS score ≥4 Screening and Baseline - the baseline score refers to a weekly average.
- Use a bland emollient daily for at least 1 week prior to Day 1 and agree to continue using that same emollient daily at the same frequency (minimally, once daily) throughout the study.
- Participants of reproductive potential (male and female participants) must practice effective methods of contraception as per protocol.
Exclusion Criteria:
Participants are excluded if they:
- Have any clinically significant medical condition or physical/laboratory/ECG/vital signs abnormality that would, in the opinion of the investigator, put the participant at undue risk or interfere with interpretation of study results.
- Have clinically significant abnormalities in any of the clinical laboratory evaluations at Screening or Baseline as determined by the Investigator.
- Have the presence of any concomitant skin conditions (eg, psoriasis, seborrheic dermatitis) or have large tattoos that would interfere with clinical assessment, evaluation of AD, or treatment response as determined by the investigator.
- Have an ongoing clinically significant skin infection or is receiving treatment for infection that may interfere with assessment of AD as determined by the investigator.
- Are pregnant or breastfeeding or are planning to become pregnant during the duration of the study and for 90 days after the last administration of study drug.
- Are taking or have taken any prespecified prohibited therapies within a specific timeframe as determined by the Investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo Arm
|
Matching oral tablet that does not contain active drug.
Administered once daily by mouth for 12 weeks under the same conditions as the investigational product.
|
|
Experimental: ENV-294 Treatment Arm (Dose 1)
|
ENV-294 is an orally administered investigational drug supplied as tablets.
Participants receive ENV-294 once daily by mouth for 12 weeks.
|
|
Experimental: ENV-294 Treatment Arm (Dose 2)
|
ENV-294 is an orally administered investigational drug supplied as tablets.
Participants receive ENV-294 once daily by mouth for 12 weeks.
|
|
Experimental: ENV-294 Treatment Arm (Dose 3)
|
ENV-294 is an orally administered investigational drug supplied as tablets.
Participants receive ENV-294 once daily by mouth for 12 weeks.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percent change in Eczema Area and Severity Index (EASI) score
Time Frame: Baseline to Week 12
|
Baseline to Week 12
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
vIGA Response
Time Frame: Baseline to Week 12
|
Proportion of participants who achieve a ≥2-point reduction from Baseline in validated Global Investigator Assessment (vIGA) score and a score of 0 or 1.
|
Baseline to Week 12
|
|
Incidence of Treatment Emergent Adverse Events
Time Frame: Baseline to Week 12 and Week 16
|
Baseline to Week 12 and Week 16
|
|
|
EASI-75 Response
Time Frame: Baseline to Week 12
|
Proportion of participants with at least 75% reduction from Baseline in EASI score
|
Baseline to Week 12
|
|
Percent change in Scoring Atopic Dermatitis (SCORAD)
Time Frame: Baseline to Week 12
|
Baseline to Week 12
|
|
|
Patient-Reported Outcomes
Time Frame: Baseline to Week 12
|
Change in Patient Oriented Eczema Measure (POEM)
|
Baseline to Week 12
|
|
Patient-Reported Outcomes
Time Frame: Baseline to Week 12
|
Peak Pruritus Numerical Rating Scale (PP-NRS): proportion of participants who achieve weekly mean decrease from Baseline of ≥4 points
|
Baseline to Week 12
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Gurpreet Ahluwalia, PhD, Enveda Therapeutics, Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ENV-294-202
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.